Jan 29, 2024 / 01:30PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Sarepta Therapeutics Program Update Conference Call. (Operator Instructions) As a reminder, today's program is being recorded. At this time, I'll turn the call over to Doug Ingram, President and Chief Executive Officer. Please go ahead.
Douglas S. Ingram - Sarepta Therapeutics, Inc. - President, CEO & Director
Thank you, Michelle, and thanks, everyone, for joining us this morning. Next slide.
Before we begin, I'll remind you to please look to our public filings for a discussion of the various risks and uncertainties that's associated with making forward-looking statements or predictions about the future.
Next slide. We are very pleased to report the results from MOMENTUM Part B, the study examining the expression and safety of SRP-5051 our next-generation peptide conjugated PMO therapy for the treatment of Duchenne patients amenable to Exon 51 skipping. As you'll see SRP-5051, if successful, could be a significant advancement over the current gold standard oligonucleotide therapy for
Sarepta Therapeutics Inc To Provide Program Update Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot